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Ebola virus (EBOV), a filovirus family member, is a highly pathogenic virus that causes Ebola 
hemorrhagic fever (EHF) resulting in documented mortality rates in humans as high as 50%. 
Currently, the basic EBOV virus-like particle (VLP) vaccine contains the Ebola virus (EBOV) 
matrix VP40 and attachment glycoprotein (GP). VLPs are morphologically and biochemically 
similar to parental virus, yet because they lack a genome and cannot replicate, are safe enough to 
be used as vaccines. We hypothesize that addition of a constitutionally active retinoic acid-
inducible gene 1 (RIG-I) would enhance the ability of the vaccine to induce interferon-dependent 
immune functions yielding an improved vaccine. Expression of EBOV VP40 in 293T cells induces 
the spontaneous production of VLPs into the media supernatant and if expressed with EBOV GP, 
will produce VLPs studded with the attachment GP. Recombinant chimeric constitutively active 
(ca)RIG-I-VP40 matrix and a nonfunctional mutant L58A (mu)RIG-I-VP40 matrix genes were 
constructed to produce VLPs containing constitutively active and nonfunctional RIG-I. 
Supernatant from 293Ts transfected with caRIG-I-VP40, muRIG-I-VP40 or VP40 along with GP 
expression plasmids were tested for the presence of VLPs. Western blotting of purified VLPs 
confirmed the presence of RIG-I in caRIG-I-VP40 and muRIG-I-VP40, but not VP40 containing 
VLPs. Monocyte-like and PMA-differentiated macrophage-like THP-1 Dual cells were treated 
with nothing, VP40+GP, caRIG-I-VP40+GP, muRIG-I-VP40+GP VLPs as well as LPS and a 
Vaccinia virus (VACV-70) positive controls and tested for induction of interferon (IFN) signaling. 
CaRIG-I containing, but not muRIG-I containing VLPs induced interferon signaling from both 
macrophages and monocytes. These results lead us to conclude that supplemented CaRIG-I would 





 Ebola Zaire (EBOV) shares the Filoviridae family with four other species of highly 
virulent Ebolaviruses; Bundibugyo, Sudan, Reston and Tai Forest, based on location of 
discovery. EBOV is an enveloped, negative-sense RNA virus holding the highest mortality rate 
ranging 60-90% (Kadanali et. al, 2015). The first recorded case of EBOV occurred in 1976 in 
sub-Saharan Africa, and the most recent, serious outbreak occurred in 2014 in West Africa which 
claimed 11,000 lives. Between 1976 and 2014, outbreaks have normally been contained quickly 
due to effective implementation of public health safety measures to prevent spread. With respect 
to the 2014 outbreak that had a record number of cases, host disease processes have been more 
meticulously studied (Ploquin et. al, 2018).  
 
The incubation period for EBOV in humans is approximately 2-21 days, with the virus 
being detectable in blood only during acute infection. Acute infections can initially be mild and 
present with fever, myalgias, malaise, gastrointestinal issues, and maculopapular rash (Kadanali 
et. al, 2015). Lethal EBOV infections involve internal and external hemorrhaging, secondary to 
coagulopathy, with more than half of affected patients suffering from severe systemic viremia 
and multisystem organ failure. The extent of viremia was a strong predictor of fatality and was 
closely monitored in some treatment settings throughout hospital admission (Faye et. al, 2015). 
EBOV outbreaks initially are a result of zoonotic transmission or handling of infected animals 
and their body fluids. Human-to-human transmission occurs primarily through handling of 
infectious body fluids during care or death investigation, rituals, and laboratory exposures. This 
virus has been classified as a Biosafety Level (BSL)-4 pathogen, requiring stringent personal 
protective measures and protocol for study, due to lethality and lack of treatment options 
(Martines et. al, 2015). 
  
 Antigen Presenting Cells (APCs) including monocytes, macrophages, and dendritic cells 
(DCs) are exceptionally susceptible to EBOV infection and are sites of viral amplification. 
Undifferentiated monocytes are more restrictive, but the addition of EBOV to monocytes induces 
differentiation into macrophages (Martinez et. al, 2013). EBOV moves beyond the site of 
infection, via blood and lymphatic systems, to infect organs like the liver and kidneys along with 
regional lymphatic organs. This access to cells of the mononuclear phagocytic system removes 
the need to infiltrate tissue or cell barriers of target organ tissues (Martines et. al, 2015). 
  
 EBOV expresses at least eight proteins; the nucleoprotein (NP), viral protein (VP) 35, 
VP40, glycoprotein (GP), VP30, VP24, and polymerase (L). The viral GP binds with several 
target host cell surface proteins including non-specific C-Type lectins (CLECs)  and 
Phosphatidylserine (PtdSer) receptors) to mediate entry (Yu et. al, 2017). CLECs and PtdSer 
receptors collectively represent at least 8 recognition domains, 2 protein complexes, and a family 
of 3 receptor tyrosine kinases which facilitate entry and attachment events (Moller-Tank & 
Maury, 2015). The outer envelope of the virus contains a trimer of GP, a class I fusion protein 
composed of covalently linked processed GP products, GP1 and GP2. GP1 being the receptor 
binding subunit, and GP2 being the fusion subunit. After initial internalization, or 
macropinocytosis of EBOV, cathepsins B & L process GP1 in the early and late endosome to 
allow GP1 to interact with host protein Niemann-Pick C1 (NPC-1) and GP2 to fuse to the 
endosomal membrane (Salata et. al, 2019). Specifically, GP2 fusion loop forms a transmembrane 
bundle containing two heptad repeat domains, leading to fusion of host and viral membranes 
allowing the viral RNA to exit the endosome and be released into the cytoplasm for replication 
(Yu et. al, 2017). 
 
 The cytoplasm of host cells is home to cytoplasmic pattern-recognition receptors (PRRs) 
that are important for activation of immune responses against intracellular pathogens. The PRR 
Retinoic Acid Inducible Gene-I (RIG-I) activates type I interferon production when viral genetic 
material, specifically 5’PPP-ssRNA or dsRNA is sensed. Viral replication of EBOV, and other 
negative-sense RNA viruses like vesicular stomatitis, is inhibited upon the activation of RIG-I 
(Spiropoulou et. al, 2009). Initial viral replication induces RIG-I and/or MDA5 to activate 
serine/threonine kinases to phosphorylate IRF-3 and 7. This promotes IFN-A/B gene expression 
for the paracrine production of type 1 interferon to signal the presence of virus infection. EBOV 
VP35 inhibits interferon production (Messaoudi et. al, 2015). 
 
 EBOV Virus-Like Particles (VLPs) are induced when VP40 is expressed in a cell. VLPs 
are similar to the parent virus that bud from the membrane of infected cells. These VLPs lack the 
genes necessary for replication, virulence, and pathogenicity; making them safe for study outside 
of BSL-4 laboratories (Marcinkiewicz et. al, 2014). Budding of the VLPs takes place in the 
intracellular membrane, plasma membrane, or multivesicular bodies. VLPs housing VP40, GP, 
and NP can be used as a vaccine and show a protective role in experimental animal models of 
EBOV infection (Falasca et. al, 2015).  
  
 VLPs have shown promise as novel vaccines. VLPs pose less risk than attenuated viral 
vaccines that may revert to wild type. They are able to produce a response in both cell-mediated 
and humoral immune responses. For example, the vaccine against human papilloma virus (HPV) 
is a VLP vaccine (Fuenmayor et. al, 2017). In another study, vaccinating mice with EBOV VLPs 
exhibited increases in CD40, 80, and 86 with MHC Class I & II, and increased secretion of IL-6, 
IL-10 and macrophage inflammatory protein (MIP)-1a, all signs of immune activation. Cell 
mediated immunity was also demonstrated in the activation of CD19+ B-Cells, along with CD4+ 
and CD8+ T-Cells. Furthermore, anti-EBOV antibodies induced by VLPs provided protection 
from lethal EBOV challenge in mice (Warfield et. al, 2003).  
 
Adjuvants are used frequently in combination with antigens in vaccines to safely induce a 
stronger immune response in the recipient.  Some of the most common adjuvants used include 
mineral salts, microparticles, microbial products, and emulsions. These adjuvants are noted to 
promote sustained antigen release and cellular recruitment at injection site, increase antigen 
uptake and presentation to APCs, and up-regulate production of cell signaling molecules (Awate 
et. al, 2013). One example includes the addition of a dsRNA-like adjuvant called polyinosinic-
polycytidylic acid (poly-IC) or its derivative, poly-IC poly-L-lysine carboxymethylcellulose 
(poly-ICLC). Poly-IC as an adjuvant proven to be effective at inducing anti-EBOV antibodies for 
immunity, but protection isn’t entirely dependent on anti-EBOV antibodies. Antibody-
independent B-Cell protection mechanisms still requires further investigation (Cooper et. al, 
2017).  
 
Another type of vaccine candidate for EBOV is a live-attenuated recombinant vesicular 
stomatitis virus that expresses the EBOV GP. Also called V920, this vaccine was tested and 
approved by the FDA and named ERVEBO (Eisele, 2019). It was uniquely stable in conditions 
that would render other vaccines and its components unusable in the field within low-income 
countries with little access to proper storage. It provided generally effective protection for at 
least two years and yielded a good risk-benefit analysis. Although this protection tapered, there 
are some clinically significant adverse effects including, but not limited to; fever, 
myalgia/arthralgia, arthritis, headaches, thrombocytopenia, leukopenia, lymphopenia, 
monocytosis and increases in liver enzymes. Along with the adverse side effects being 
investigated, children exhibited high levels of rVSV in the plasma and viremia beyond a week 
post-vaccination with viral shedding in urine and saliva (Bache et. al, 2020). An additional study 
using a similar rVSV-EBOV vaccine with a smaller sample size indicated the need for a second 
dose. The second dose yielded increased antibody titers at almost 2 months and reduced adverse 
effects, but the protection from the antibodies diminished after 6 months (Regules et. al, 2015).  
 
The purpose of this study is to determine whether addition of a constitutively active RIG-





Materials & Methods 
 
Plasmids 
We transformed competent cells with vectors expressing six different EBOV proteins. 
The viral proteins include EBOV GP, GPF88A (Mutant on Gene 88, single base, Phenylalanine 
to Argenine), RIG-I Wild Type and Mutant (L58A), Recombinant Vesicular Stomatitis Virus (r-
VSV), Flag VP40, and VP40 B-Lactamase.  
 
Cell Preparation and Maintenance 
293T Cells were maintained in Dulbecco’s Modified Eagle Medium supplemented with 
10% fetal bovine serum, and APS (Amphotericin B, Penicillin, and Streptomycin) solution. Cells 
were incubated at 37°C under 5% CO2. 
 
Maxi-Preparations of Expression Vectors 
Maxi-Preparations were performed using the Plasmid Plus Maxi Kit (QIAGEN, 
Germantown, MD)to purify plasmid DNA per manufacturer instructions, using DNA. 
 
Calcium Phosphate Transfection of Expression Vectors 
Performed Day 1 of Calcium Phosphate Transfection Protocol from the Calcium 
Phosphate Transfection Kit for a 100mm dish (Invitrogen, Carlsbad, CA) 
In summary, two solutions were prepared and used to create a mixture to add to 293T 
cells. Solution A containing purified, sterile DNA was mixed with multiple plasmids at a ratio of 
3:1:1 for the first 5 plasmid mixtures, and 1:1 for the last plasmid mixture (see table 1). Solution 
A contains DNA mixture, sterile H2O, and 1M CaCl2 (Table 1). Solution B solely contained 2X 
Hepes Buffered Saline (HBS). Solution A was slowly added to solution B over the course of two 
minutes and incubated at room temperature for 20 minutes, and then added dropwise to cells in 
two separate 10cm dishes. Transfected cells incubated for 72 hours at 37°C under 5% CO2.  
 
 
VLP Harvest and Purification 
 All work with VLPs was completed in a sterile hood to maintain consistent aseptic 
technique. Cells were pelleted out of harvested supernatant continaing VLPs before layering onto 
a sucrose cushion to enrich for VLPs.   
Purification of the VLPs consisted of two cycles of ultracentrifugation at 100,000Gs for 
2.5 hours at 10°C through a 20% sucrose cushion. Supernatant was aspirated after each spin, but 
PBS was carefully added after the first cycle, and removing the remaining sucrose cushion with 
the supernatant occurred at the end of the second spin. The pellet consisted of VLPs and was 
resuspended in 100uL of NTE buffer (filtered through a 0.2 micron filter to ensure sterility). 
Samples incubated on ice overnight sealed with parafilm, then were moved to microcentrifuge 
tubes.  
 
Quantification of VLPs- β-Lactamase Assay 
 Quantification of VLPs was measured using relative fluorescence in a black microplate 
using Molecular Devices Spectramax i3x spectrophotometer (Company name, central office city, 
state) and was analyzed with SoftMax Pro software. The plate was bottom-read at a wavelength 
of 535 nm, 495 nm excitation, and medium shake for 5 seconds before the first read at each time 
interval.  
 The stock solution used to fill the microplate for each sample of VLP consisted of 1mL 
PBS (with Mg2+ and Ca2+)/Cytobuster, 10uL of fluorocillin, and 20uL of assigned VLP. 50uL of 
the solution was added to each well in duplicate for each of the 6 VLPs, were sealed in parafilm 
and covered for darkness, to incubate at room temperature (25°C). The plate was read at time 
intervals of 20 minutes, 30 minutes, and 3.5 hours (Figure 1). 
 
Monocyte Isolation  
Four anonymous donors (A, B, Y, and Z) gave 28mL of Whole Human Blood each and 
was collected in standard 4mL EDTA (Purple Top) Vacutainer Tubes. Y and Z were harvested 
first, then A and B were harvested in a repeat of this protocol. Each subject’s blood products 
were placed into designated 50mL tornado tubes (Red Tops), and continually mixed to prevent 
coagulation. Blood was diluted 1:2 with Hank’s Buffered Saline Solution (HBSS) in preparation 
for monocyte isolation.  
Initial isolation of monocytes and removal of platelets were completed by following the 
GE Healthcare Ficoll-Paque PLUS protocol per manufacturer instructions with the following 
modifications. The pellet of PBMCs were resuspended for monocyte isolation. 
The BioLegend MojoSort™ Human Pan Monocyte Isolation Kit (Company name, central 
office city, state) was used, per manufacturer instructions, with the following modifications. The 
Platelet Removal Procedure was not performed. We analyzed cell viability and quantity of viable 
cells with the ViaCell XR Cell Counter prior to adding Human TruStain FcX™ (Fc Receptor 
Blocking Solution), Biotin Antibody Cocktail, and the magnetic Streptavidin Nanobeads. To 
perform this, the pellet from samples Y and Z in the Ficoll-Paque PLUS protocol were 
resuspended in 10.5mL of MojoSort Buffer provided in the kit. The pellets from samples A and 
B in the second round of enacting this protocol were resuspended in 11mL of 
MojoSort™  buffer. 0.5mL of resuspended pellet samples Y and Z were diluted 1:2 with HBSS 
for cell counting, while samples A and B were not diluted and solely used resuspended product. 
The volume of Human TruStain FcX™ (Fc Receptor Blocking Solution), Biotin 
Antibody Cocktail, and the magnetic Streptavidin Nanobeads used in this protocol based on the 
Total Viable Cells count on the cell counter with confirmation by manual hemocytometry (Table 
2). Incubation times, centrifugation, magnet use for liquid fractions for gathering unlabeled cells 
remained according to protocol.  
The fractions are quantified for viable cells using 0.5mL of cells and 0.5mL of 
MojoSort™ buffer in the ViaCell XR after aforementioned protocol was completed.  
 
Monocyte Culturing 
Monocytes isolated from this protocol were cultured in two clear 96-well plates with 
RPMI supplemented with 5% Human Sera (Fischer Scientific Catalog #: BP2651700), 
amphotericin, penicillin, streptomycin (APS). Cells were incubated overnight at 37°C at 5% CO2 
to allow monocyte adherence to the wells.  
 
Monocyte Stimulation with Virus-Like Particles  
After overnight incubation, monocytes were treated with the six different VLPs and three control 
reagents including positive controls; lipopolysaccharide (LPS) and VacV in triplicate; and one 
section with no VLP or reagent. Plates are incubated overnight at 37°C at 5% CO2 to allow VLPs 
to interact with the monocytes. The extent to which monocytes were stimulated is indicated by 
the amount of interferon secreted into the culturing media. After stimulation, 150 micoliters were 
harvested and then replaced. This process was repeated every 24 hours for 96 hours. Harvested 
supernatant was frozen until assayed.  
 
Interferon Production Measurement  
20 microliters of supernatants from the monocyte stimulation assays were added to an IFN-β & 
NF- κβ reporter THP-1 Dual™ Cells (Invivogen, San Diego, CA). THP-1 Dual Cells and 
incubated for 48 hours. Using the Molecular Devices Spectramax i3x spectrophotometer and 
analysis with the SoftMax Pro software, we were able to assay for amounts of secreted luciferase 
(luminescence) proportional to interferon signaling.  
 
Results 
 The VLPs were created to stimulate human peripheral blood monocytes and measure 
production of interferon from each VLP preparation (Table 1).  We incorporated wild-type (wt) 
vesicular stomatitis virus attachment protein G as a control, viral protein 40 (VP40) to produce 
the VLP, and a constitutively active RIG-I to test for interferon induction in VLP preparations. 
The GPF88A is a mutated glycoprotein with an amino acid change from Phenylalanine to 
Alanine at the 88th gene position that no longer functions in entry in order to test for the effects 
of entry on interferon induction (Martinez et. al, 2015). The RIG-I mutant control has an amino 
acid change from Lysine to Alanine at the 58th amino acid position which prevents binding to 
viral K63 polyubiquitin chains preventing IRF3 activation by RIG-I CARDs (caspase activation 
and recruitment domains) and inhibiting IFN-β production (Jiang et. al, 2012).  
To normalize for amounts of VLPs, VLP quantification was measured in Relative 
Fluorescence Units (RFU) using spectrophotometry (Figure 1). Flag VP40 yielded the highest 
RFU among the others at 3.32 RFU. Flag VP40 was followed by GPF88A (1) at 2.23 RFU and 
RIG-I-wt/r-VSV (1) at 1.98 RFU.  
To test whether VLPs could induce interferon from human monocytes, VP40+GP, 
caRIG-I-VP40+GP, muRIG-I-VP40+GP VLPs as well as LPS and a Vaccinia virus (VACV-70) 
were added into monocyte cultures from two blood donors for four days. Supernatant was 
removed in 24-hour intervals and stored for testing IFN presence using THP-1 Dual reporter 
cells.   
 Relative Luminescence indicated the amount of interferon in the supernatant from the 
monocyte stimulation with VLP preparations. Lipopolysaccharide (LPS) and vaccinia virus 
(VACV) both served as positive controls. LPS was used as a positive control given it is highly 
recognized as a PAMP with extracellular PRRs, specifically TLR-4, with an endotoxic effect on 
human cells (Bertani & Ruiz, 2018). VACV (InvivoGen VACV-70/LyoVec™) serves a positive 
control due to its ability to profoundly induce IFN-β .  
Measuring bioluminescence is the result of THP-1 DUAL reporter cell secretion of 
luciferase into the media indicating presence and quantity of interferon. Between the two 
monocyte groups, Human Monocytes 1 and Human Monocytes 2 (HM1 & 2), HM1 consistently 
produced IFN in all samples provided. THP-DUAL cells alone had produced 66 RFU. RIG-I wt 
containing VLPs induced the greatest average IFN-production at 1255.67 and 763 RFU from 
HM1 and HM2, respectively. MRIG-I produced 56.67 and 303.3 RFU, respectively. Positive 
controls, LPS and VACV, showed 121 and 170.67 RFU then 214.5 and 0 RFU. VSV-g produced 
1.33 and 167.3 RFU. Mutant GPs, GPF88A-1 and GPF88A-2, showed 37 and 62 RFU then 0 
and 93 RFU. Flag VP40 yielded 63.3 and 83.67 RFU. Finally, THP-1 Dual Cells alone yielded 





We successfully created VLP preparations to test in interferon stimulation assays. The 
VLP preparation that created the most VLPs was the VP40 combined with GP consistent with 
studies by Dr. Ilhem Messaoudi at University of California-Riverside, California, USA (2015) 
and Dr. Laura Falasca with National Institute for Infectious Diseases, Lazzaro Spallanzani, 
Rome, Italy (2015).  Spectrophotometry values (RFU) when measuring amount of VLPs and IFN 
are qualitative measurements of quantity and do not enumerate particles or concentration of IFN 
in solution.  
 Magnitude of interferon production from each VLP was compared with the positive 
controls, LPS and VACV. The RIG-I wild type containing VLP with the first human monocyte 
group yielded 10 times the amount of interferon production in monocyte stimulation when 
compared to LPS. LPS still didn’t yield nearly as much interferon alone as the supplemented 
RIG-I wt did. THP-1 DUAL Cell blank, or the negative control, in the first human monocyte 
group exhibited luciferase secretion likely due to minute stimulation from the media or basal 
luciferase secretion independent of stimulatory material. mRIG-I, being the second highest 
interferon stimulator within the second human monocyte group, induced 1.7 times the amount of 
interferon in comparison to LPS. We surmise that newly plated monocytes are less reactive to 
positive controls due to lack of development in culture, expression of associated PRR’s, or 
activation of other molecular mechanisms required for a substantial reaction. Ultimately, 
increased interferon production with the VP40/RIG-I wt/GP VLP preparation was attained as a 
result of adding a constitutionally active RIG-I. The combination of GP, and its capacity to 
mediate entry into the target monocyte of VLPs that release active RIG-I into the cytoplasm 
leads to the production of interferon and potentially to enhance the cellular and humoral immune 
response. While the wild type RIG-I remained consistent, the mutated GP (GPF88A) showed its 
inability to properly enter the monocyte to induce production of IFN. Overall, our results are 
consistent with our hypothesis that the addition of constitutionally active RIG-I induces 
interferon production from human monocytes, which may enhance vaccine efficacy. 
Additionally, it provides additional understanding on the effect of viral particles in vaccines with 
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Figure 2. THP-1 Dual Reporter Cells Interferon Measurement in Relative Fluorescence Units  
 
 
